Neoadjuvant Chemotherapy Plus Immunotherapy in Early-Stage Resectable Non-Small-Cell Lung Cancer
- PMID: 35714306
- DOI: 10.1200/JCO.22.00873
Neoadjuvant Chemotherapy Plus Immunotherapy in Early-Stage Resectable Non-Small-Cell Lung Cancer
Abstract
The Oncology Grand Rounds series is designed to place original reports published in the Journal into clinical context. A case presentation is followed by a description of diagnostic and management challenges, a review of the relevant literature, and a summary of the authors' suggested management approaches. The goal of this series is to help readers better understand how to apply the results of key studies, including those published in the Journal of Clinical Oncology, to patients seen in their own clinical practice.
Similar articles
-
Management of Patients With EGFR Exon 20-Mutant Advanced Non-Small Cell Lung Cancer.J Clin Oncol. 2025 May;43(13):1527-1533. doi: 10.1200/JCO-24-02624. Epub 2025 Mar 7. J Clin Oncol. 2025. PMID: 40053885 Review.
-
Neoadjuvant Chemotherapy in Colon Cancer: More Than Just an Optical Illusion.J Clin Oncol. 2024 Sep 1;42(25):2949-2954. doi: 10.1200/JCO.24.00220. Epub 2024 Jul 25. J Clin Oncol. 2024. PMID: 39052952 Review.
-
Combination Immunotherapy With Nivolumab Plus Ipilimumab in Melanoma of Unknown Primary.J Clin Oncol. 2025 Mar 10;43(8):907-911. doi: 10.1200/JCO-24-01802. Epub 2025 Feb 6. J Clin Oncol. 2025. PMID: 39913893 Review.
-
Challenge of Rechallenge: When to Resume Immunotherapy Following an Immune-Related Adverse Event.J Clin Oncol. 2019 Oct 20;37(30):2714-2718. doi: 10.1200/JCO.19.01623. Epub 2019 Aug 28. J Clin Oncol. 2019. PMID: 31461381
-
Axillary Surgery for Patients With Residual Isolated Tumor Cells (ypN0i+) After Neoadjuvant Systemic Therapy for Early Breast Cancer.J Clin Oncol. 2025 Mar;43(7):771-775. doi: 10.1200/JCO-24-01711. Epub 2024 Nov 12. J Clin Oncol. 2025. PMID: 39531609 Review.
Cited by
-
Perioperative Chemo-Immunotherapy in Non-Oncogene-Addicted Resectable Non-Small Cell Lung Cancer (NSCLC): Italian Expert Panel Meeting.Curr Oncol. 2025 Feb 14;32(2):110. doi: 10.3390/curroncol32020110. Curr Oncol. 2025. PMID: 39996910 Free PMC article. Review.
-
Revamping Non-Small Cell Lung Cancer Treatments in Stages II and III: Preparing Healthcare for Cutting-Edge Immuno-Oncology Regimens.Cancers (Basel). 2024 Aug 14;16(16):2842. doi: 10.3390/cancers16162842. Cancers (Basel). 2024. PMID: 39199613 Free PMC article.
-
Comprehensive analysis and identification of subtypes and hub genes of high immune response in lung adenocarcinoma.BMC Pulm Med. 2024 Jul 4;24(1):324. doi: 10.1186/s12890-024-03130-6. BMC Pulm Med. 2024. PMID: 38965571 Free PMC article.
-
Neoadjuvant chemoimmunotherapy cycle number selection for non-small cell lung cancer and clinical outcomes: a real-world analysis.Front Oncol. 2023 Sep 5;13:1200625. doi: 10.3389/fonc.2023.1200625. eCollection 2023. Front Oncol. 2023. PMID: 37731645 Free PMC article.
-
Tumor-associated macrophages affect the treatment of lung cancer.Heliyon. 2024 Apr 6;10(7):e29332. doi: 10.1016/j.heliyon.2024.e29332. eCollection 2024 Apr 15. Heliyon. 2024. PMID: 38623256 Free PMC article. Review.
Publication types
MeSH terms
LinkOut - more resources
Full Text Sources
Medical